Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -40.00 -3.1% 1,252.00 1,246.00 1,254.00 1,300.00 1,246.00 1,284.00 33,106 16:35:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 86.4 12.6 20.0 62.6 620

Ergomed Share Discussion Threads

Showing 1001 to 1019 of 1025 messages
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
DateSubjectAuthorDiscuss
29/1/2023
11:03
Richard Barfield has been extremely impressive so very grateful for his contribution to the transformation of ERGO. He will be a difficult act to follow. However, the strategy is set and the execution going exceedingly well so his contribution will be sustained.

He has a c. 1m options on shares which is equivalent to about 2% of ERGO, so we'll have to see what he does with these. Hopefully he'll retain a sizeable holding in ERGO and an informal, if not formal, advisory role in future.

Apart from that I like to express my thanks as a shareholder and wish him a very long and very, very happy retirement. If you share my sentiments please give this post a thumbs-up.

Cheers Maddox

maddox
27/1/2023
10:19
better he retired then jumped ship to another company. IMHO.
mfhmfh
26/1/2023
16:00
"Richard Barfield retiring is a big negative ..."

LOL, no doubt conspiracy theories abound

"he sold a large part of his shareholding last year - I took his cue and sold out then"

So what?. He cashed in 125,000 10p options and has plenty more

piedro
26/1/2023
15:11
RB's retirement a very big negative sign. he sold a large part of his shareholding last year - I took his cue and sold out then
qvg
26/1/2023
12:28
Richard Barfield retiring is a big negative on the stock unfortunately. In short he transformed his previous company and then Ergomed - check the share price after he was appointed .The retirement expectation was on the wall when the deputy CFO was appointed. I sold half before the announcement and the other half yesterday.
ihatemms
26/1/2023
10:56
Positive trading update. https://uk.advfn.com/stock-market/london/ergomed-ERGO/share-news/Ergomed-plc-Ergomed-2022-Trading-Update/90051338?xref=newsalert

But no move in share price. Likely due to the still high PE ratio in an era where PEs have reduced a lot.

fegger
14/10/2022
15:34
Octopus holdings {from my records}
piedro
10/10/2022
11:06
PrimeVigilance@PrimeVigilance
EVENT – Greetings from Tokyo! We are so pleased to be a first-time exhibitor
at the DIA Japan Annual Meeting.
If you are attending, look up Booth #19 and stop by to meet our team from our
regional hub in Tokyo.

piedro
27/9/2022
16:06
It is a service business
Productivity improvements are probably limited

phillis
27/9/2022
12:19
Updated chart ...



- that is what I wanted to see: cost growth moderated

piedro
27/9/2022
09:46
Another very impressive web-cast today.
ihatemms
26/7/2022
11:32
Ergomed cheers 'very strong' performance in first half of 2022

hTTps://www.youtube.com/watch?v=FpZVQuZlTUU

piedro
26/7/2022
09:54
Excellent update for interims and H2 outlook particularly order book. glad I topped up recently.
adorling
26/7/2022
09:47
Business as usual update,
but can they keep costs under control?

piedro
25/7/2022
11:22
let's see what tomorrow brings
mfhmfh
10/6/2022
07:18
Update looks good to me.
capitalist
29/3/2022
10:22
Includes £3m contingent earn out deemed employment cost
phillis
29/3/2022
07:08
Super results yet again - above expectations. This stock deserves a premium rating.
ihatemms
17/2/2022
17:27
...from last year...

Company overview:
Founded in 1997, Ergomed plc is a specialist services provider for the pharmaceutical industries, covering all phases of clinical development, post-approval pharmacovigilance and medical information. The company operates in more than 100 countries through its Pharmacovigilance and Clinical research Outsourcing service lines. The company has made several acquisitions over the past 5 years.
Last three years’ performance is categorized by steady growth in Revenue, gross Profit and adjusted EBITDA and order book growth in 2020 of 55.5%. Acquisition in 2020 was in the USA with ambition to increase market presence for both business lines. Revenue in USA is currently accounting for around 54%, compared to UK’s 14% and EU area 27%. Latest update from the company shows strong trade with 38% growth in revenue in the first half of the year bringing the interim figure to £56m. CRO division generated a staggering 90.7%. Healthy balance sheet and prospects for growth are firmly supported by increase in cash balance to £24.6m and growth in order book at 18% since 01/01/2021....from WealthOracleAM

https://wealthoracle.co.uk/detailed-result-full/ERGO/46

km18
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
Your Recent History
LSE
ERGO
Ergomed
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230207 01:01:13